UnitedHealth Group Inc.: Q1 FY2026 earnings call

What management said about Q1 FY2026, from the documents filed with the SEC on 21 April 2026: press release. Guidance figures: 2 raised, 2 new, 1 kept. The quarter’s numbers.

Read the filing

Key takeaways

• Revenue rose 2% to $111.7 billion: Revenues were $111.7 billion, up from $109.6 billion a year earlier. Earnings from operations were $9.0 billion against $9.1 billion. Source
• Medical care ratio down 90 basis points: The medical care ratio was 83.9%, compared with 84.8% a year earlier. The company cited cost management and favorable reserve development. Source
• UnitedHealthcare margin rose to 6.6%: UnitedHealthcare revenues were $86.3 billion and earnings from operations were $5.7 billion. Management attributed the margin change mainly to repricing. Source
• Optum margin fell to 5.2%: Optum revenues were $63.7 billion and earnings were $3.3 billion, against $3.9 billion a year earlier. Margin was 5.2% against 6.1%. Source
• Operating cost ratio rose to 13.8%: The operating cost ratio was 13.8% against 12.4% a year earlier. Management tied the increase to artificial intelligence and other investments. Source
• Full-year EPS guidance raised: Diluted EPS guidance rose from greater than $17.10 to greater than $17.35, and adjusted EPS guidance rose from greater than $17.75 to greater than $18.25. Source
• At least $2.0 billion buyback by Q2: The company entered an arrangement to repurchase at least $2 billion of common stock, expected to be completed by the end of the second quarter 2026. Source

“We are continuing to help simplify and modernize health care for the people and care providers we serve, bringing greater value, affordability, transparency and connectivity,”

Stephen Hemsley, chief executive officer of UnitedHealth Group

Guidance

What changed from last quarter

• Guidance raised: Full-year 2026 diluted EPS guidance raised from greater than $17.10 to greater than $17.35; adjusted EPS guidance raised from greater than $17.75 to greater than $18.25. Source
• New guidance: Company entered an arrangement to buy back at least $2 billion of common stock, expected to be completed by end of Q2 2026. Source
• New: Company agreed to acquire Alegeus Technologies, a benefits administration platform for consumer-directed health accounts. Source
• New: Organization refocused on U.S. health care, with non-U.S. businesses being exited. Source
• New: Optum Financial, including Optum Bank, moved from Optum Health into Optum Insight as part of a realignment. Source
• New: Board changes included a new Public Responsibility Committee, a Lead Independent Director, new committee chairs and a new independent director. Source
• New: Nearly half of the top 100 leadership roles were refreshed. Source

Consolidated first quarter results

• Revenue rose 2% to $111.7 billion: Revenues were $111.7 billion, up from $109.6 billion a year earlier. Earnings from operations were $9.0 billion against $9.1 billion. Source
• Diluted EPS of $6.90 and adjusted $7.23: Diluted EPS was $6.90 against $6.85 a year earlier, and adjusted EPS was $7.23 against $7.20. Net margin was 5.6% against 5.7%. Source
• Operating cash flow of $8.9 billion: Cash flows from operations were 1.4 times net income, and debt-to-capital was 42.9% at March 31, 2026. Source
• Medical care ratio down 90 basis points: The medical care ratio was 83.9%, compared with 84.8% a year earlier. The company cited cost management and favorable reserve development. Source

UnitedHealthcare results and membership

• UnitedHealthcare margin rose to 6.6%: UnitedHealthcare revenues were $86.3 billion and earnings from operations were $5.7 billion. Management attributed the margin change mainly to repricing. Source
• Membership down to 49.1 million: Members served fell from 49.8 million at year end 2025. Medicare Advantage seniors served declined by 965,000 in the quarter. Source
• Employer group added 415,000 people: Employer and Individual revenues were $20.1 billion. Growth in employer self-funded offerings was partly offset by attrition in fully-insured and individual products. Source
• Medicare and Retirement revenue up 1%: Medicare and Retirement revenues were $42.1 billion. Trend-driven repricing offset lower seniors served. Source
• Community and State revenue up 4%: Community and State people served fell by 220,000, mainly from early effects of state eligibility changes. Medicaid rate updates drove revenue growth. Source

“with performance supported by actions taken over the last several quarters.”

UnitedHealth Group Inc., press release

Optum results by business

• Optum margin fell to 5.2%: Optum revenues were $63.7 billion and earnings were $3.3 billion, against $3.9 billion a year earlier. Margin was 5.2% against 6.1%. Source
• Optum Health revenue down 3%: Optum Health earnings from operations were $1.1 billion, or $1.3 billion adjusted. Management cited continued investments and elevated medical costs. Source
• Optum Insight earnings lower: Optum Insight revenues were $5.1 billion. Management attributed lower earnings to continued investments in people, technology and new products. Source
• Optum Rx revenue up, scripts down: Optum Rx revenue rose 2% to $35.7 billion on specialty pharmacy growth. Earnings were $1.2 billion against $1.3 billion, reflecting UHC membership attrition. Source

Costs, reserves and one-time items

• Operating cost ratio rose to 13.8%: The operating cost ratio was 13.8% against 12.4% a year earlier. Management tied the increase to artificial intelligence and other investments. Source
• Loss contracts helped medical ratio: The medical care ratio included a 20 basis point positive effect from the Optum Health loss contracts reserve disclosed earlier. Source
• Foundation contribution from Optum Insight sale: Restructuring and other included a $400 million contribution to the foundation, funded by the cash gain on an Optum Insight disposition. Loss reserve reduction and equity gains partly offset it. Source
• South American losses on held-for-sale units: Net portfolio divestitures and South American impacts included incremental losses on businesses held for sale, partly offset by net gains on dispositions. Source

Full-year 2026 guidance changes

• Full-year EPS guidance raised: Diluted EPS guidance rose from greater than $17.10 to greater than $17.35, and adjusted EPS guidance rose from greater than $17.75 to greater than $18.25. Source
• Reserve reduction excluded from adjusted EPS: Projected 2026 adjusted EPS excludes a $402 million expected reduction in loss contract reserves, on top of $137 million recognized in Q1 2026. Source
• Intangible amortization excluded from adjusted EPS: Adjusted EPS excludes intangible amortization, which the company projects at about $1,325 million for 2026. Source

Capital, cash and working capital

• At least $2.0 billion buyback by Q2: The company entered an arrangement to repurchase at least $2 billion of common stock, expected to be completed by the end of the second quarter 2026. Source
• Debt-to-capital down to 42.9%: Debt-to-capital was 42.9% at March 31, 2026, against 43.9% at year end 2025 and 44.6% a year earlier. Source
• Cash position and operating cash flow: Cash and short-term investments were $31.2 billion at March 31, 2026. Operating cash flow reflected changes in working capital accounts. Source
• Days claims payable rose sequentially: Days claims payable were 48.6, up from 44.1 in the fourth quarter and 45.5 a year earlier. Management tied the change to seasonality and claims payment timing. Source
• Days sales outstanding at 21.6: Days sales outstanding was 21.6, against 18.8 in the fourth quarter and 22.3 a year earlier. Management described the change as normal seasonality. Source

Portfolio and strategy actions

• Refocus on U.S. health care: The organization is refocusing on U.S. health care and exiting non-U.S. businesses, listed among actions taken. Source
• Alegeus acquisition agreed: The company agreed to acquire Alegeus Technologies, a platform for consumer-directed health accounts. The deal is subject to regulatory review. Source
• Artificial intelligence and cybersecurity investment: Simplification and modernization include substantial artificial intelligence and cybersecurity investments, along with changes to interoperability, prior authorization and pharmacy practices. Source
• Optum Financial moved into Optum Insight: Optum Financial, including Optum Bank, moved from Optum Health into Optum Insight from January 1, 2026. Reportable segments are unchanged and prior periods were recast. Source

Leadership and governance

• Nearly half of top leaders refreshed: The company refreshed nearly half of its top 100 leadership roles as part of initiatives begun in the second half of 2025. Source
• Board committee and director changes: A Public Responsibility Committee was created and a Lead Independent Director named. New committee chairs were installed, a new independent director added, and board recruiting accelerated. Source
• Community engagement through foundation: Community engagement and support through the United Health Foundation was increased, according to the release. Source

Coming up, as management said on 21 April 2026

• Share repurchase completion by Q2: The company expects to repurchase at least $2.0 billion of common stock by the end of the second quarter 2026. Source
• Alegeus closing in back half: The Alegeus acquisition is expected to close in the back half of 2026, subject to regulatory review, and to be earnings neutral to 2026. Source
• Debt-to-capital target timing: The company expects to reach its long-term debt-to-capital target of about 40.0% in the back half of 2026. Source

Figures management reported

Risks management discussed

• Operational: Utilization and unit cost trends remained elevated and partly offset the lower medical care ratio. Source
• Demand: Lower volume from membership attrition at UHC reduced Optum Rx earnings, alongside investments in people. Source
• Regulatory: Community and State people served fell by 220,000, mainly from early effects of state eligibility changes. Source
• Financial: Claims payment timing and seasonality affected the sequential change in days claims payable. Source

Earlier plans management reported on

• Not stated: The company continues to build on initiatives begun in the second half of 2025 across operations, technology and governance. Source
• Not stated: The company expects to reach its debt-to-capital target of about 40.0% in the back half of 2026. Source
• Not stated: The company expects to repurchase at least $2.0 billion of common stock by the end of the second quarter 2026. Source

Other quarters

• Q2 FY2026 earnings call
• Q4 FY2025 earnings call
• Q3 FY2025 results
• Q2 FY2025 results

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.